Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 518

1.

Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.

Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C.

J Clin Virol. 2009 Jul;45 Suppl 1:S55-61. doi: 10.1016/S1386-6532(09)70009-5.

PMID:
19651370
2.

Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.

Getman D, Aiyer A, Dockter J, Giachetti C, Zhang F, Ginocchio CC.

J Clin Virol. 2009 Jul;45 Suppl 1:S49-54. doi: 10.1016/S1386-6532(09)70008-3.

PMID:
19651369
3.

Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.

De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca N.

J Virol Methods. 2008 Jan;147(1):10-7. Epub 2007 Sep 12.

PMID:
17854914
4.

Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.

Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A.

J Clin Microbiol. 2011 Feb;49(2):557-64. doi: 10.1128/JCM.02147-10. Epub 2010 Dec 8.

5.

[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].

Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.

Zhonghua Yi Xue Za Zhi. 2006 Feb 7;86(5):307-11. Chinese.

PMID:
16677522
6.

Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.

Sandri MT, Lentati P, Benini E, Dell'Orto P, Zorzino L, Carozzi FM, Maisonneuve P, Passerini R, Salvatici M, Casadio C, Boveri S, Sideri M.

J Clin Microbiol. 2006 Jun;44(6):2141-6.

7.

Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.

Keegan H, Mc Inerney J, Pilkington L, Grønn P, Silva I, Karlsen F, Bolger N, Logan C, Furuberg L, O'Leary J, Martin C.

J Virol Methods. 2009 Jan;155(1):61-6. doi: 10.1016/j.jviromet.2008.09.027. Epub 2008 Nov 13.

PMID:
18955086
8.

Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.

Huang S, Erickson B, Tang N, Mak WB, Salituro J, Robinson J, Abravaya K.

J Clin Virol. 2009 Jul;45 Suppl 1:S19-23. doi: 10.1016/S1386-6532(09)70004-6.

PMID:
19651364
9.

An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.

Thai H, Rangwala S, Gay T, Keating K, McLeod S, Nazarenko I, O'Neil D, Pfister D, Loeffert D.

J Clin Virol. 2009 Jul;45 Suppl 1:S93-7. doi: 10.1016/S1386-6532(09)70014-9.

PMID:
19651375
10.

Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.

Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A.

J Clin Microbiol. 2010 Aug;48(8):2779-85. doi: 10.1128/JCM.00382-10. Epub 2010 Jun 23.

11.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
12.

Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.

Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C.

J Virol Methods. 2009 Mar;156(1-2):77-83. doi: 10.1016/j.jviromet.2008.11.002. Epub 2008 Dec 17.

PMID:
19041893
14.

Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.

Kang WD, Kim CH, Cho MK, Kim JW, Kim YH, Choi HS, Kim SM.

Int J Gynecol Cancer. 2009 Jul;19(5):924-8. doi: 10.1111/IGC.0b013e3181a832a2.

PMID:
19574786
15.

Analytical characterization of the APTIMA HPV Assay.

Dockter J, Schroder A, Eaton B, Wang A, Sikhamsay N, Morales L, Giachetti C.

J Clin Virol. 2009 Jul;45 Suppl 1:S39-47. doi: 10.1016/S1386-6532(09)70007-1.

PMID:
19651368
16.

[Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].

Guo YL, You K, Geng L, Zhang XW, Shen XY, Yao YJ, Fan XH.

Beijing Da Xue Xue Bao. 2006 Oct 18;38(5):480-2. Chinese.

17.

Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear.

Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Quinzat D, Dachez R, Syrjänen K.

Int J STD AIDS. 2008 Jun;19(6):385-92. doi: 10.1258/ijsa.2007.007259.

PMID:
18595876
18.

Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.

Reuschenbach M, Clad A, von Knebel Doeberitz C, Wentzensen N, Rahmsdorf J, Schaffrath F, Griesser H, Freudenberg N, von Knebel Doeberitz M.

Gynecol Oncol. 2010 Oct;119(1):98-105. doi: 10.1016/j.ygyno.2010.06.011. Epub 2010 Jul 8.

PMID:
20619445
19.

Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.

Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N.

J Clin Microbiol. 2011 Mar;49(3):1071-6. doi: 10.1128/JCM.01674-10. Epub 2010 Dec 29.

20.

Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia.

Monsonego J, Pintos J, Semaille C, Beumont M, Dachez R, Zerat L, Bianchi A, Franco E.

Int J Gynecol Cancer. 2006 Mar-Apr;16(2):591-8.

PMID:
16681731

Supplemental Content

Support Center